Whetstone Capital Advisors LLC Invests $202,000 in Kenvue Inc. (NYSE:KVUE)

Whetstone Capital Advisors LLC acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 8,745 shares of the company’s stock, valued at approximately $202,000.

A number of other institutional investors have also modified their holdings of KVUE. Riverview Trust Co bought a new position in shares of Kenvue during the third quarter valued at approximately $30,000. Ashton Thomas Securities LLC bought a new position in Kenvue during the 3rd quarter worth $35,000. Deseret Mutual Benefit Administrators increased its position in Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after buying an additional 651 shares during the period. Studio Investment Management LLC boosted its holdings in shares of Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after acquiring an additional 845 shares during the period. Finally, AlphaMark Advisors LLC bought a new position in shares of Kenvue during the third quarter worth about $77,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $24.11 on Monday. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.31. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average of $22.84 and a two-hundred day moving average of $20.87. The company has a market capitalization of $46.23 billion, a price-to-earnings ratio of 43.78, a PEG ratio of 2.19 and a beta of 1.36.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the prior year, the business earned $0.31 earnings per share. As a group, analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be given a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.40%. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on KVUE shares. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Jefferies Financial Group assumed coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective for the company. Piper Sandler raised their target price on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. Royal Bank of Canada lowered Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. raised their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.